Background and Approval
This disclosure is in continuation to the company's earlier intimation dated April 30, 2026, where the Board of Directors approved the incorporation of a Wholly Owned Subsidiary (WOS) in Dubai.
Subsidiary Incorporation Details
The WOS has been incorporated under the name "DR LAL PATHLABS FZCO" on June 12, 2026. The company received the Certificate of Incorporation/License on the same date from the Dubai Multi Commodities Centre (DMCC) authority.
Investment Structure
The company subscribed to the share capital of DR LAL PATHLABS FZCO amounting to AED 19,135,000 (United Arab Emirates Dirhams Nineteen Million One Hundred Thirty-Five Thousand Only). This investment is divided into 19,135 shares of AED 1,000 each.
Ownership and Control
Dr. Lal PathLabs Limited holds 100% shareholding in the subsidiary company.
Business Purpose and Strategy
The wholly owned subsidiary intends to strategically invest in diagnostics and allied activities. This includes exploring potential acquisitions, tie-ups, or joint ventures in the diagnostic services industry.
Transaction Details
- Consideration Type: Cash consideration
- Industry: Diagnostic Services
- Related Party Transaction: Not applicable
- Government Approvals: Not applicable
- Completion Timeframe: Not applicable (already completed)
Financial Impact
The investment represents a cash outflow of AED 19,135,000 (approximately ₹43.40 crore at current exchange rates) for 100% ownership of the newly incorporated entity.